Literature DB >> 25320591

Lipodystrophy syndrome among HIV infected children on highly active antiretroviral therapy in northern India.

Euden Bhutia1, Alok Hemal1, Tribhuvan Pal Yadav1, K L Ramesh2.   

Abstract

BACKGROUND: It is estimated that about 2.5 million people are living with HIV infection in India. Although antiretroviral drugs have been able to reduce the mortality, these drugs have serious side effects one of which is lipodystrophy syndrome. Most of the drugs used in HAART viz, protease inhibitors, stavudine and nevirapine are associated with lipodystrophy. Hence we conducted this study to assess the prevalence of lipodystrophy in HIV infected children on HAART and its associated risk factors.
MATERIALS AND METHODS: A cross sectional study was conducted on 80 HIV infected children aged 2-18 years of age who were on stavudine based HAART for ≥ 2 years. These children were assessed for presence of lipodystrophy, its metabolic complications and associated risk factors.
RESULTS: Lipodystrophy was observed in 33.7% of children with lipoatrophy being the commonest subtype followed by lipohypertrophy. Older age, increased duration of treatment and dyslipidaemia were found to be associated in patients with lipodystrophy than those without. On further multivariate analysis of independent risk factors only increased duration of treatment was significantly associated with lipodystrophy. No association was found with insulin resistance.
CONCLUSION: We observed that lipodystrophy is a common finding in HIV patients treated with HAART for long duration.

Entities:  

Keywords:  HAART; HIV; lipoatrophy; lipodystrophy syndrome

Mesh:

Substances:

Year:  2014        PMID: 25320591      PMCID: PMC4196396          DOI: 10.4314/ahs.v14i2.17

Source DB:  PubMed          Journal:  Afr Health Sci        ISSN: 1680-6905            Impact factor:   0.927


  32 in total

1.  HIV-associated lipodystrophy syndrome: A review of clinical aspects.

Authors:  Jean-Guy Baril; Patrice Junod; Roger Leblanc; Harold Dion; Rachel Therrien; Franãois Laplante; Julian Falutz; Pierre Côté; Marie-Nicole Hébert; Richard Lalonde; Normand Lapointe; Dominic Lévesque; Lyse Pinault; Danielle Rouleau; Cécile Tremblay; Benoãt Trottier; Sylvie Trottier; Chris Tsoukas; Karl Weiss
Journal:  Can J Infect Dis Med Microbiol       Date:  2005-07       Impact factor: 2.471

Review 2.  Antiretoviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis.

Authors:  D Nolan; M John; S Mallal
Journal:  Antivir Ther       Date:  2001-09

3.  Prevalence of lipodystrophy in HIV-infected children in Tanzania on highly active antiretroviral therapy.

Authors:  Grace D Kinabo; Mirte Sprengers; Levina J Msuya; Aisa M Shayo; Henri van Asten; Wil M V Dolmans; Andre J A M van der Ven; Adilia Warris
Journal:  Pediatr Infect Dis J       Date:  2013-01       Impact factor: 2.129

4.  Prevalence of lipodystrophy in HIV-infected children: a cross-sectional study.

Authors:  Luminita Ene; Tessa Goetghebuer; Marc Hainaut; Alexandra Peltier; Véronique Toppet; Jack Levy
Journal:  Eur J Pediatr       Date:  2006-07-29       Impact factor: 3.183

5.  A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.

Authors:  T Saint-Marc; M Partisani; I Poizot-Martin; F Bruno; O Rouviere; J M Lang; J A Gastaut; J L Touraine
Journal:  AIDS       Date:  1999-09-10       Impact factor: 4.177

6.  Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+ -lymphocyte count and CD4+ -lymphocyte percentage at baseline and use of protease inhibitors and stavudine.

Authors:  S M Arpadi; P A Cuff; M Horlick; J Wang; D P Kotler
Journal:  J Acquir Immune Defic Syndr       Date:  2001-05-01       Impact factor: 3.731

7.  Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children.

Authors:  D Jaquet; M Lévine; E Ortega-Rodriguez; A Faye; M Polak; E Vilmer; C Lévy-Marchal
Journal:  AIDS       Date:  2000-09-29       Impact factor: 4.177

8.  Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe.

Authors: 
Journal:  AIDS       Date:  2004-07-02       Impact factor: 4.177

9.  Lipodystrophy among HIV-infected children and adolescents on highly active antiretroviral therapy in Uganda: a cross sectional study.

Authors:  Thereza Piloya; Sabrina Bakeera-Kitaka; Adeodata Kekitiinwa; Moses R Kamya
Journal:  J Int AIDS Soc       Date:  2012-07-02       Impact factor: 5.396

10.  High prevalence of lipoatrophy in pre-pubertal South African children on antiretroviral therapy: a cross-sectional study.

Authors:  Steve Innes; Mark F Cotton; Richard Haubrich; Maria M Conradie; Margaret van Niekerk; Clair Edson; Helena Rabie; Sonia Jain; Xiaoying Sun; Ekkehard W Zöllner; Stephen Hough; Sara H Browne
Journal:  BMC Pediatr       Date:  2012-11-23       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.